Communiqués Prostatype Genomics AB

Actions

PROGEN

SE0023261532

Installations et services en soins de santé

Marché Fermé - Nasdaq Stockholm 18:00:00 18/09/2026			Varia. 5j.	Varia. 1 janv.
0,1560 ^SEK	-2,80%		-1,89%	-48,00%

31/08	Prostatype Genomics AB (publ) publie ses résultats pour le premier semestre clos le 30 juin 2026	CI
31/08	Prostatype Genomics obtient un soutien de 70 % pour l'exercice de ses bons de souscription de 12,5 millions de SEK	MT

Communiqués

17/09	Prostatype Genomics AB receives approximately SEK 12.5 million through the exercise of warrants of series TO6	AQ
10/09	The last day of trading in Prostatype Genomics AB’s warrants of series TO6 is tomorrow	AQ
01/09	The exercise period for warrants of series TO6 starts today	AQ
31/08	Prostatype Genomics receives commitments and letters of intent of approx. 70 percent of the exercise of warrants TO6	AQ
31/08	Prostatype Genomics publishes its interim report for the first half of 2026	AQ
05/08	Prostatype Genomics AB resolves on a directed issue	AQ
03/08	Prostatype Genomics AB announces last day of trading in BTUs and first day of trading in warrants of series TO6 and TO7	AQ
27/07	Prostatype Genomics AB announces outcome in rights issue of units	AQ
21/07	Last day for subscription in Prostatype Genomics AB's rights issue of units is July 23, 2026	AQ
09/07	The subscription period in Prostatype Genomics AB's rights issue of units begins today	AQ
08/07	Prostatype Genomics AB publishes information memorandum prior to rights issue of units	AQ
08/07	Prostatype Genomics AB enters into top-down underwriting ahead of upcoming rights issue of units	AQ
30/06	Prostatype Genomics : provides financing update	PU
29/06	The Board of Directors of Prostatype Genomics AB resolves on the previously announced rights issue of units of approximately SEK 47.4 million	AQ
22/06	Bulletin from annual general meeting in Prostatype Genomics AB (publ)	AQ
01/06	Prostatype Genomics publishes Annual Report for 2025	AQ
25/05	Update from Prostatype Genomics Regarding the Medicare Reimbursement Process for Prostatype® in the United States	AQ
19/05	Prostatype Genomics AB announces the Board of Directors’ intention to resolve on a rights issue of units of approximately SEK 47.4 million	AQ
26/02	Prostatype Genomics publishes year-end report for 2025	AQ
12/01	Loan financing of SEK 10 million to Prostatype Genomics AB	AQ
08/01	Prostatype Genomics U.S. Validation study by Veterans Affairs (VA) is published	AQ
25/11	Prostatype Genomics' Newsletter: Update on Medicare application and publication of U.S. study results	AQ
11/11	Previous Investments in Research and Development Unlock Hidden Assets in Prostatype Genomics	AQ
24/09/25	New shares from exercise of warrants of series TO5 registered	AQ
18/09/25	Prostatype Genomics AB receives SEK 11.5 million in connection with warrants of series TO5	AQ